|Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS||
||Industry / Other||
||326||All||18 Years to 80 Years (Adult, Senior)||NCT00573443||07-AVR-123||STAR||December 2007||June 2009||September 2009||December 14, 2007||April 12, 2017||July 10, 2013||
|2||NCT01832350||Active, not recruiting||Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease||
||Other / Industry||
||60||All||55 Years to 90 Years (Adult, Senior)||NCT01832350||AVP923||December 2012||November 2017||December 2017||April 16, 2013||July 12, 2017||
† Study has passed its completion date and status has not been verified in more than two years.